With a 5-year minimum follow-up, clinically meaningful OS benefit was maintained with nivolumab plus ipilimumab versus chemotherapy in Japanese patients regardless of tumor PD-L1 expression, despite a high rate of subsequent immunotherapy received in the chemotherapy arm (81%) in the combined PD-L1 ≥ 1% and < 1% population of patients with a PFS event. Here, CD274 is linked to neoplasm.